LY2334737
CAS No. 892128-60-8
LY2334737 ( LY2334737; gemcitabine prodrug )
Catalog No. M17645 CAS No. 892128-60-8
LY2334737 is an orally available prodrug of gemcitabine with antineoplastic activity.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 119 | In Stock |
|
5MG | 178 | In Stock |
|
10MG | 267 | In Stock |
|
25MG | 447 | In Stock |
|
50MG | 644 | In Stock |
|
100MG | 888 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLY2334737
-
NoteResearch use only, not for human use.
-
Brief DescriptionLY2334737 is an orally available prodrug of gemcitabine with antineoplastic activity.
-
DescriptionLY2334737 is an orally available valproic acid ester of gemcitabine, a broad-spectrum antimetabolite with antineoplastic activity. LY2334737 is hydrolyzed by carboxylesterase 2 (CES2) and releases gemcitabine systemically over a period of time consistent with formation rate-limited kinetics. In turn, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate and triphosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually the induction of apoptosis. Compared to gemcitabine, this prodrug is able to avoid hydrolysis in enterocytes and the portal circulation thus avoiding first pass metabolism and increasing systemic gemcitabine availability.
-
SynonymsLY2334737; gemcitabine prodrug
-
PathwayCell Cycle/DNA Damage
-
TargetPotassium Channel
-
RecptorOthers
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number892128-60-8
-
Formula Weight389.39
-
Molecular FormulaC17H25F2N3O5
-
Purity98%
-
SolubilityDMSO : ≥ 100 mg/mL; 256.81 mM
-
SMILESC(=O)(C(CCC)CCC)Nc1nc(=O)n(cc1)[C@@H]1O[C@@H]([C@H](C1(F)F)O)CO
-
Chemical NameN-(1-((2S,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)-2-propylpentanamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Pratt SE, et al. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 2013 Mar 1;19(5):1159-68.
molnova catalog
related products
-
IK1 inhibitor PA-6
IK1 inhibitor PA-6 (PA-6) is a selective and potent inhibitor of IK1.
-
Tertiapin-Q
A high affinity blocker for inward-rectifier K+ channels, this compound is a stable derivative of the bee venom toxin tertiapin. Binds to ROMK1 (Kir1.1) and GIRK1/4 (Kir3.1/3.4) channels with high affinity (Ki values are 1.3 and 13.3 nM respectively) and is selective over Kir2.1 channels. Derivative tertiapin LQ also available.
-
PD-118057
A potent, selective hERG potassium channel (Kv11.1) activator that increases peak tail hERG current of 111.1% at 10 uM in HEK293 cells.